[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumocystis-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumocystis-pneumonia":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,67,103,134,156,180,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100645390","derivation-and-validation-of-the-fungal-pneumonia-assessment-and-likelihood-predictor-score-100645390",false,"NCT07681583","Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score","FUNGAL-P","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years.\n* Presentation to the Emergency Department or hospital with pneumonia.\n* Pneumonia defined according to IDSA\u002FATS criteria as the presence of at least two clinical signs or symptoms of lower respiratory tract infection (temperature \\\u003C36.0°C or \\>38.0°C, respiratory rate \\>20 breaths\u002Fmin, oxygen saturation \\\u003C90% on room air, arterial PaO₂ \\\u003C60 mmHg, cough, sputum production, white blood cell count \\\u003C4,000\u002FμL or \\>10,000\u002FμL, or bandemia \\>10%) together with radiographic evidence of a new pulmonary infiltrate or cavitary lesion.\n* Bronchoalveolar lavage (BAL), bronchial aspirate (BAS), or endotracheal aspirate (ETA) performed within 48 hours of hospital presentation.\n* Modified Rankin Scale score \\\u003C5.\n* Availability of microbiological investigations for identification of fungal, bacterial, or viral pathogens.\n* Provision of informed consent, when required by applicable regulations and ethics committee approval.\n\nExclusion Criteria:\n\n* Refusal or withdrawal of informed consent.\n* Age \\\u003C18 years or \\>90 years.\n* Pregnancy.\n* Expected life expectancy \\\u003C3 months.\n* Hospital-acquired pneumonia with onset \\>48 hours after hospital admission.\n* Modified Rankin Scale score ≥5.\n* Absence of microbiological diagnostic evaluation.\n* No identified bacterial, fungal, or viral pathogen after microbiological investigations.","ALL","18 Years","90 Years",{"count":20,"type":21},400,"ESTIMATED","30 Days","OBSERVATIONAL","The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.\n\nThe study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.\n\nThe derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.",[26,27,28,29,30,31,32,33,34,35],"Pneumonia","Fungal Pneumonia","Aspergillosis Pneumonia","Pulmonary Aspergillosis","Pulmonary Aspergillosis Invasive","Pneumocystis","Pneumocystis Pneumonia","Fungal Disease","Fungal Infection","Fungal Infection Lungs",[27,37,29,38,32,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Aspergillus","Pneumocystis jirovecii","Coinfection","Community-Acquired Pneumonia","CAP","Risk Prediction","Clinical Prediction Rule","Clinical Risk Score","FUNGAL-P Score","SCORE","Bronchoalveolar Lavage","Emergency Department","Internal medicine","Infectious disease","Diagnostic Accuracy","Risk Factors","Respiratory Infection","RECRUITING","2026-06-26",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":58},"2025-11-13",{"date":62,"type":21},"2031-11-13",{"name":64,"class":65},"Azienda Ospedaliero-Universitaria Careggi","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":88,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":66},"100427823","phase-3-low-dose-trimethoprim-sulfamethoxazole-for-the-treatment-of-pneumocystis-jirovecii-pneumonia-100427823","NCT04851015","Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia","LOW-DOSE","Inclusion Criteria:\n\n* 18 years or older\n* Immunocompromised (including but not limited to HIV, solid organ transplant, solid tumors, hematological stem cell transplant and malignancies, systemic diseases, chemotherapy, long term corticosteroid use, and immunosuppressive therapies, as well as primary immunodeficiencies\n* Presentation to a day hospital, emergency department, or admitted to hospital\n* Proven or probable diagnosis of PCP using an adapted version of the 2021 EORTC\u002FMSGERC criteria.\n\nExclusion Criteria:\n\n* Previous severe adverse reaction to TMP-SMX, any sulfa drug, or any component of formulation\n* Compliant with PCP prophylaxis for ≥4 weeks with TMP-SMX at enrollment\n* More than 96 hours of any therapy for PCP\n* Hepatic impairment marked by alanine aminotransferase levels ≥5 times the upper limit of normal\n* Known G6PD deficiency\n* Known diagnosis of porphyria\n* Known pregnancy or breastfeeding (as per Health Canada)\n* Unable to provide informed consent and no available healthcare proxy (with ethics approval for deferred consent in cases of critical illness); refusal of consent; no reliable means of outpatient contact (telephone\u002Femail\u002Ftext);\n* Previously enrolled","100 Years",{"count":76,"type":21},416,"INTERVENTIONAL",[79],"PHASE3","Pneumocystis jirovecii pneumonia (PCP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg\u002Fkg\u002Fday of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX.\n\nReduced treatment doses of TMP-SMX for PCP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg\u002Fkg\u002Fday of TMP) compared to the standard-of-care (15 mg\u002Fkg\u002Fday) among patients with PCP for the primary outcome of Win Ratio hierarchical composite of death, ECMO, invasive ventilation, grade 4 toxicity, non-invasive ventilation, change of therapy and length of stay.",[31,32,82,83,84,85,86,87],"Pneumocystis Jirovecii Infection","Pneumocystis Infections","Pneumocystis Carinii Infection","Pneumocystosis; Pneumonia (Etiology)","Pneumocystis Carinii; Infection, Resulting From HIV Disease","Pneumocystosis Associated With AIDS",[31,89,90,91,92,93],"PCP","PJP","immunosuppressed","HIV","TMP-SMX","2026-02-18",{"date":96,"type":58},"2026-02-20",{"date":98,"type":58},"2025-11-28",{"date":100,"type":21},"2030-12-31",{"name":102,"class":65},"Todd C. Lee MD MPH FIDSA",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":77,"phases":112,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":66},"100618235","phase-4-how-long-should-we-give-steroids-for-patients-with-severe-pcp-100618235","NCT07328984","How Long Should we Give Steroids for Patients With Severe PCP","How Long Should we Give Steroids for Patients With Severe PCP (HOW LONG)","HOW LONG","Inclusion Criteria:\n\n* Age ≥18 years\n* Proven or probable Pneumocystis jirovecii pneumonia\n* Severe PCP requiring supplemental oxygen (e.g., ≥4 L\u002Fmin or ≥35% FiO₂ to maintain SpO₂ ≥94%)\n* Planned or receiving adjunctive systemic corticosteroid therapy for severe PCP\n* Clinical recovery by day 10 of steroid therapy: breathing room air for ≥6 hours\n* Able to provide informed consent (or per local requirements)\n\nExclusion Criteria:\n\n* Persistent hypoxemia or ongoing oxygen requirement at day 10\n* Clinical deterioration prior to randomization\n* Treating clinician determines steroids must be continued or stopped immediately for medical reasons\n* Anticipated death within 48 hours\n* Inability or unwillingness to complete follow-up through day 180",{"count":76,"type":21},[113],"PHASE4","The HOW LONG trial is an international, multicenter, Phase IV randomized clinical trial evaluating the optimal duration of adjunctive systemic corticosteroids in immunocompromised adults with severe Pneumocystis jirovecii pneumonia (PCP) who demonstrate early clinical recovery. Participants who no longer require supplemental oxygen by day 10 of corticosteroid therapy are randomized to discontinue corticosteroids at day 10 (or hospital discharge, if earlier) versus continue corticosteroids for a total of 21 days. The trial assesses whether earlier discontinuation reduces steroid-related complications while maintaining clinical outcomes.",[32,31,82,116,86,87,85],"Pneumocystis Jiroveci Pneumonia",[89,118,119,120,121,92,122,123],"Systemic Corticosteroids","De-escalation of Therapy","Randomized Control Trial","Immunocompromised host","Non-HIV","Pneumocystis jirovecii pneumonia","NOT_YET_RECRUITING","2025-12-27",{"date":127,"type":58},"2026-01-09",{"date":129,"type":21},"2026-01-30",{"date":131,"type":21},"2029-06",{"name":133,"class":65},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100550075","pneumocystis-jirovecii-genotyping-100550075","NCT06442345","Pneumocystis Jirovecii Genotyping","Real-time Pneumocystis Jirovecii Genotyping to Support Clinical Decision Making in the Management of Nosocomial Outbreaks","Inclusion Criteria:\n\n* Total nucleic acid extracts from adult patients (over 18 years old) with a positive PCP diagnosis (\\& detected at \\> 50 copies\u002F10ul) from routine respiratory panel testing.\n\nExclusion Criteria:\n\n* Total nucleic acid extracts from patients with a negative PCP diagnosis from routine respiratory panel testing\n* Total nucleic acid extracts from non-adult patients (under 18 years old).\n* PCP positive total nucleic extract samples with \\\u003C 50 copies\u002F10ul.\n* Patients included on the UK National Opt-Out register",{"count":142,"type":21},70,"We share our lives with microorganisms, and these generally do not pose a problem if an individual is healthy with a normal immune system. However, if the immune system was not functioning properly (e.g., cancer patients), they are at risk of infection. One microorganism, a fungus called Pneumocystis jirovecii (PCP), can cause severe chest infections in patients without properly functioning immune systems, leading to hospitalisation and death if untreated. If patients remain without a functioning immune system, they have a greater chance of repeated infection.\n\nPCP spreads through air from person-to-person and can survive on environmental surfaces. Patients can be infected after contact with these surfaces. Hospitals have a responsibility to ensure PCP infected patients do not pass it on to other unwell patients. In cases where PCP has infected multiple patients, knowing if the same fungi has been passed along (or transmitted) from patient-to-patient is vital in understanding if there is an outbreak in the hospital. Understanding how similar (the relatedness) the PCP strain is allows healthcare workers to detect any transmission between patients or the environment.\n\nTo understand how related each patient's PCP infection is we will utilise a laboratory test called multilocus sequence typing (MLST). This test looks at sections of the fungi's genetic code using deoxyribonucleic acid (DNA) sequencing to create a code (genotype) which tells us how related one PCP is to others tested, allowing comparison between patients and ultimately spotting transmission.\n\nOur aim is to develop this sequencing test using PCP positive patient samples and ensure it performs to high-quality standards. Surplus material from seventy known PCP positive patient samples will be tested. Each sample will be analysed to see if the DNA genotype matches or is similar to other patient samples we have tested, helping to understand how PCP may spread between patients.",[32],[89,146],"Genotyping","2025-06-24",{"date":149,"type":58},"2025-06-27",{"date":151,"type":21},"2025-09",{"date":153,"type":21},"2026-01",{"name":155,"class":65},"Nottingham University Hospitals NHS Trust",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":77,"phases":165,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":179},"100503455","phase-2-rezafungin-for-treatment-of-pneumocystis-pneumonia-in-hiv-adults-100503455","NCT05835479","Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults","A Phase 2, Proof-of-Concept, Multicentre, Open-Label, Randomised, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rezafungin Combined With 7 Days of Co-Trimoxazole Versus Co-Trimoxazole Monotherapy in HIV-Infected Adults With Pneumocystis Jirovecii Pneumonia","Inclusion Criteria:\n\n1. Males or females at least 18 years of age.\n2. Tested positive for HIV by either blood antigen\u002Fantibody combination HIV-1\u002F2 immunoassay, HIV-1\u002FHIV-2 antibody differentiation immunoassay, or nucleic acid tests (e.g., HIV ribonucleic acid \\[RNA\\] polymerase chain reaction \\[PCR\\]). Participants who are newly diagnosed with HIV infection by an antigen\u002Fantibody combination HIV-1\u002F2 immunoassay are allowed to be included in the study, but the infection should be subsequently confirmed by an HIV-1\u002FHIV-2 antibody differentiation immunoassay or nucleic acid tests.\n3. Diagnosed with definitive, presumptive, or clinically suspected PCP prior to randomisation.\n4. Willing and able to provide written informed consent. If the participant is unable to provide consent, a legally acceptable representative (i.e., acceptable to ICH and local law, as applicable) must provide informed consent on the participant's behalf.\n5. Participants of childbearing potential (all biologically female participants between 18 years and \\\u003C2 years post-menopausal unless surgically sterile) must agree to use a highly effective contraceptive measure during the study period (from enrolment) and for at least 30 days after the last dose of rezafungin.\n6. Biologically male participants who are not vasectomised must agree to the following requirements during the study period (from enrolment) and for at least 120 days after the last dose of rezafungin:\n\n   * Refrain from donating sperm PLUS, either\n   * Abstain from sexual intercourse with a female of childbearing potential as their preferred and usual lifestyle OR\n   * Use barrier contraception (i.e., male condom with or without spermicide) when having sexual intercourse with a female of childbearing potential who is not currently pregnant.\n\nExclusion Criteria:\n\n1. Under 18 years of age.\n2. Known or suspected hypersensitivity or allergic reaction to co-trimoxazole, rezafungin, any echinocandin, or any component of these formulations, including, but not limited to, anaphylaxis or exfoliative skin disorders (e.g., Stevens-Johnson syndrome or toxic epidermal necrolysis).\n3. Any contraindication to co-trimoxazole or intake of a medication or supplement known to severely interact with co-trimoxazole as detailed in the Summary of Product Characteristics (SmPC) of co-trimoxazole, including, but not limited to, acute porphyria or a history of drug-induced immune thrombocytopaenia with use of trimethoprim and\u002For sulphonamides.\n4. Creatinine clearance \\\u003C15 mL\u002Fmin or receiving renal replacement therapy.\n5. Severe hepatic impairment, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>5 × upper limits of normal (ULN), or total bilirubin \\>3 × ULN, or a history of chronic cirrhosis (Child-Pugh score \\>9).\n6. A neutrophil count \\\u003C1,000 cells\u002FµL or a platelet count \\\u003C50,000 cells\u002FµL.\n7. Immunosuppressive disease other than HIV \u002F acquired immunodeficiency syndrome (AIDS) (e.g., haematopoietic stem cell transplant, solid organ transplant, or primary immune deficiencies) OR prolonged use of immune-weakening medications:\n\n   * Having received corticosteroids equivalent to prednisone ≥20 mg daily for at least 14 consecutive days within 30 days prior to study entry, or\n   * Having received biologics (e.g., infliximab, ustekinumab), immunomodulators (e.g., methotrexate, mercaptopurine, azathioprine), or cancer chemotherapy within 90 days prior to study entry.\n8. Previously diagnosed with PCP and having received treatment in the past 6 weeks.\n9. Receiving therapy for PCP at approved therapeutic doses for \\>48 hours before randomisation. Exception: receipt of an anti-PCP drug at prophylactic doses (i.e., lower than approved therapeutic doses).\n10. Meeting National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 criteria for ataxia, tremors, motor neuropathy, or sensory neuropathy of Grade 2 or higher.\n11. History of severe ataxia, tremors, or neuropathy or a diagnosis of multiple sclerosis or a movement disorder (including Parkinson's disease and Huntington's disease).\n12. Planned or ongoing therapy at Screening with a known severe neurotoxic medication or with a known moderate neurotoxic medication in a participant with ataxia, tremors, motor neuropathy, or sensory neuropathy of NCI-CTCAE version 5.0 Grade 1 or higher.\n13. Previous participation in this or any other rezafungin study.\n14. Female participants who are pregnant or lactating.\n15. Having a concomitant disease or any medical condition (including other HIV-associated infection or complication) that, in the opinion of the Investigator, could pose undue risk to the participant, impede completion of the study procedures (e.g., patients who are not expected to survive even with treatment), or would compromise the validity of the study measurements.\n16. Receipt of an investigational drug within 30 days prior to dosing of the study drug(s), presence of an investigational device at the time of Screening, or is planning to participate in another interventional clinical study while enrolled in this study.\n17. The Investigator is of the opinion the participant should not participate in the study.\n\nLate Exclusion Criteria:\n\nThe diagnosis of PCP will be reviewed by the Investigator on Day 8 (before dosing the study drug). Participants will be withdrawn from the study if any of the following criteria apply (i.e., participants without a diagnosis of definitive or presumptive PCP on Day 8):\n\n1. Lack of positive P. jirovecii immunofluorescence or PCR of bronchoalveolar lavage, endotracheal aspirates, bronchoscopic tissue biopsy, or induced sputum AND serum β-D-glucan below the positive cut-off value.\n2. Serum β-D-glucan below the positive cut-off value in participants in whom collection of a suitable respiratory sample is not possible.\n3. Radiographic features on chest CT performed after randomisation not consistent with PCP after taking into account the clinical and microbiological findings.",{"count":164,"type":21},50,[166],"PHASE2","This study aims to generate clinical data on the efficacy, safety, and tolerability of rezafungin combined with 7 days of co-trimoxazole for treatment of Pneumocystis pneumonia (PCP) in adults living with human immunodeficiency virus (HIV), which would expand the knowledge of clinical use of rezafungin.",[32],"2025-04-02",{"date":171,"type":58},"2025-04-03",{"date":173,"type":58},"2023-11-14",{"date":175,"type":21},"2025-08",{"name":177,"class":178},"Mundipharma Research Limited","INDUSTRY",6,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":77,"phases":190,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":66},"100584715","phase-1-casponeb-efficacy-and-safety-of-caspofungin-aerosols-for-the-curative-treatment-of-pneumocystis-pneumonia-100584715","NCT06892951","CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia","Phase I\u002FII Safety lead-in Randomized Blind Placebo-controlled Clinical Trial: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia in Adjunction of Conventional Systemic Antifungal Therapy","CaspoNEB","Inclusion criteria:\n\n* Male and female ≥18 years\n* Medical management of Pneumocystis pneumonia based on :\n\n  * Microbiological diagnosis of Pneumocystis pneumonia\n  * Respiratory support (oxygen therapy or ventilatory assistance)\n  * Systemic co-trimoxazole therapy or systemic second-line anti-Pneumocystis salvage therapy (switch to another anti-Pneumocystis drug is possible, but should be notified) (initiated within 48 hours or less before enrolment)\n* Person affiliated to a French social security system or equivalent\n* Written informed consent obtained from the participant or, if the patient is not able to give consent from representative (trusted person, family member) or if the delay in obtaining the consent is assumed not compatible with the enrollment requirements, a temporary approval can be obtained from the investigator. In all cases, the patient's written informed consent will have to be obtained as soon as possible.\n\nNon-inclusion criteria:\n\n* Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship). Pregnancy test to be performed in all women from 15 to 45 years old who have not had an ovariectomy.\n* Other indication(s) for systemic administration of an echinocandin drug\n* Known allergy to echinocandin drugs\n* Absolute contraindication to aerosol therapy\n* Concomitant co-infection at time of diagnosis (except HIV infection)\n* Severe liver impairment (i.e. documented severe liver cirrhosis (Child C), or Factor-V protein \\\u003C 50% and\u002For INR for prothrombin time of blood coagulation \\> 1.5)\n* history of toxic epidermal necrosis (TEN) and Steven-Johnson syndrome (SJS)\n* Participation in other pharmacological study that focuses on echinocandins and\u002For anti-infectious aerosol therapy or other anti-pneumocystis treatment\n* Participation in a trial with an investigational product known to have pulmonary toxicity or of which the safety is not known",{"count":189,"type":21},100,[191,166],"PHASE1","To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a \"GO \u002F NO GO\" decision towards a phase III trial of nebulized caspofungin in those patients.",[32,82,83],[195,31,196,197,198,199,200,201],"ventilation","caspofungin","echinocandin","aerosol","inhalation","nebulization","interstitial pneumonia","2025-03-17",{"date":204,"type":58},"2025-03-25",{"date":206,"type":21},"2025-06",{"date":208,"type":21},"2028-12",{"name":210,"class":65},"University Hospital, Tours",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":66},"100569213","caspofungin-for-pneumocystis-pneumonia-in-plwhiv-100569213","NCT06691321","Caspofungin for Pneumocystis Pneumonia in PLWHIV.","Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV\u002FAIDS.","Inclusion Criteria:\n\n* Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section).\n* Have clinical laboratory and virological diagnostic laboratory studies at the time of admission.\n\n  * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.:\n\nProven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism.\n\nExclusion Criteria:\n\n* With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).\n* Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.","60 Years",{"count":220,"type":21},60,"Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV\u002FAIDS, often severe and potentially fatal. While trimethoprim\u002Fsulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.",[223,32],"HIV-1-infection",[123,225,226],"Echinocandins","Caspofungin","2024-11-15",{"date":229,"type":58},"2024-11-19",{"date":231,"type":58},"2023-08-01",{"date":233,"type":21},"2025-09-01",{"name":235,"class":236},"Instituto Nacional de Enfermedades Respiratorias","OTHER_GOV"]